亖呉?盀
范文一：KSA中文资料
www.ittcannon.com
B–38
Dimensions shown in: mm (inch)
Specifications and dimensions subject to change
T a c t i l e S w i t c h e s
KSA & KSL SeriesSealed Tact Switch
?
RoHS compliant and compatible
Specification
CONTACT ARRANGEMENT:SPST, N.O.DOUBLE OVERMOLDING ON TERMINALMEMBRANE SEALING
TERMINALS:PC pins, ground pin optional
Mechanical
Electrical
Silver Gold MAXIMUM POWER:1 VA0.2 VAMAXIMUM VOLTAGE:32 VDC32 VDCMINIMUM VOLTAGE:20 mV20 mVMAXIMUM CURRENT:50 mA10 mAMINIMUM CURRENT:1 mA1 mA
DIELECTRIC STRENGTH: 300 VrmsCONTACT RESISTANCE: < 100m="">
INSULATION RESISTANCE (100 V): > 109?BOUNCE TIME: < 1="">
Environmental
Silver Gold OPERATING TEMPERATURE:-40?C to 90?C-40?C to 125?CSTORAGE TEMPERATURE:
-40?C to 90?C
-55?C to 125?C
Process
Wave soldering compatible with lead free soldering profile.
Packaging
Can be delivered in tubes of 65 pieces for automatic insertion orin boxes of 500 pieces for manual insertion (250 pieces for KSL,KSLV , KSAV).
Button Color10Dark gray20Light gray30Yellow 40Red 50Green
60Blue 70Gray-blue 80Ivory 90Black
BUTTONS Buttons must be ordered separately and will be supplied in bulk.
元器件交易网www.cecb2b.com
www.ittcannon.com
B–39
Dimensions shown in: mm (inch)
Specifications and dimensions subject to change
Tactile Switches
KSA & KSL
KSA & KSL Series
Sealed Tact Switch
元器件交易网www.cecb2b.com
Specifications and dimensions subject to change T
a
c
t
i
l
e
S
w
i
t
c
h
e
s
M MANUAL (BULK PACKAGING)
A AUTOMATIC (TUBE PACKAGING, 65 PIECES PER TUBE)
Ground terminal
PCB LAYOUT
OPTION
CODE OPERATING FORCE
21.3 N (130 grams)
100,000 operations
31.3 N (130 grams)
1,000,000 operations
43.0 N (300 grams)
100,000 operations
55.0 N (500 grams)
100,000 operations
93.0 N (300 grams)
500,000 operations
KSA & KSL Series
Sealed Tact Switch
PCB LAYOUT
元器件交易网www.cecb2b.com
www.ittcannon.com B–40
www.ittcannon.com
B–41
Dimensions shown in: mm (inch)
Specifications and dimensions subject to change
Tactile Switches
OPTION CODE
CONTACT MATERIAL
1Silver contacts3
Gold contacts
OPTION CODE
SEALING 0Sealed against flux1
Totally sealed
KSA & KSL SeriesSealed Tact Switch
BUTTONS
K01
K02
BUTTON TYPE
KSA KSL KSAV KSLV
K01X K02X K03X X X X K04X X X
X K05X X K06X
K07X X K08X
X
K09
X X
Buttons must be ordered separately and will be supplied in bulk.
元器件交易网www.cecb2b.com
www.ittcannon.com
B–42
T a c t i l e S w i t c h e s
KSA & KSL SeriesSealed Tact Switch
元器件交易网www.cecb2b.com
范文二：ADC中文资料
标签:无标签
ADC0809中文资料
ADC0809是带有 8位 A/D转换器、 8路多路开关以及微处理机兼容的控制逻辑 的 CMOS 组件。它是逐次逼近式 A/D转换器,可以和单片机直接接口。 (1) ADC0809的内部逻辑结构
由下图可知, ADC0809由一个 8路模拟开关、一个地址锁存与译码器、一个 A/D转换器和一个三态输出锁存器组成。多路开关可选通 8个模拟通道,允许 8路模拟量分时输入,共用 A/D转换器进行转换。三态输出锁器用于锁存 A/D转 换完的数字量, 当 OE 端为高电平时, 才可以从三态输出锁存器取走转换完的数 据。
(2). ADC0809引脚结构
ADC0809各脚功能如下:
D7-D0:8位数字量输出引脚。
IN0-IN7:8位模拟量输入引脚。
VCC :+5V工作电压。
GND :地。
REF (+):参考电压正端。
REF (-):参考电压负端。
START :A/D转换启动信号输入端。
ALE :地址锁存允许信号输入端。
(以上两种信号用于启动 A/D转换) .
EOC
OE :输出允许控制端,用以打开三态数据输出锁存器。
CLK :时钟信号输入端(一般为 500KHz )。
A 、 B 、 C :地址输入线。
ADC0809对输入模拟量要求:信号单极性, 电压范围是 0-5V , 必须进行放大; 输入的模拟量在转换过程中应该保持不变, 则需在输入前增加采样保持电路。
地址输入和控制线:4条
ALE 为地址锁存允许输入线,高电平有效。当 ALE 线为高电平时,地址锁存 与译码器将 A , B , C 三条地址线的地址信号进行锁存,经译码后被选中的通道 的模拟量进转换器进行转换。 A , B 和 C 为地址输入线,用于选通 IN0-IN7上 的一路模拟量输入。通道选择表如下表所示。
C B A
选择的 通道 0 0 0
IN0 0 0 1
IN1 0 1 0
IN2 0 1 1
IN3 1 0 0
IN4 1 0 1 IN5
4. ADC0809应用电路原理图
6. 程序设计内容
(1) . 进行 A/D转换时, 采用查询 EOC 的标志信号来检测 A/D
若完毕则把数据通过 P0端口读入,经过数据处理之后在数码管上显示。 (2). 进行 A/D转换之前,要启动转换的方法:
ABC =110选择第三通道
ST =0, ST =1, ST =0产生启动转换的正脉冲信号 .
C 语言源程序
#include
unsigned char code dispbitcode[]={0xfe,0xfd,0xfb,0xf7,
0xef,0xdf,0xbf,0x7f};
unsigned char code dispcode[]={0x3f,0x06,0x5b,0x4f,0x66, 0x6d,0x7d,0x07,0x7f,0x6f,0x00};
unsigned char dispbuf[8]={10,10,10,10,10,0,0,0};
unsigned char dispcount;
sbit ST=
sbit OE=
sbit EOC=
unsigned char channel=
unsigned char getdata;
void main(void)
{
TMOD=0x01;
TH0=(65536-4000)/256;
TL0=(65536-4000)%256;
TR0=1;
ET0=1;
EA=1;
P3=channel;
while(1)
{
ST=0;
ST=1;
ST=0;
while(EOC==0);
OE=1;
getdata=P0;
OE=0;
dispbuf[2]=getdata/100;
getdata=getdata%10;
dispbuf[1]=getdata/10;
dispbuf[0]=getdata%10;
}
}
void t0(void) interrupt 1 using 0 {
TH0=(65536-4000)/256;
TL0=(65536-4000)%256;
P1=dispcode[dispbuf[dispcount]]; P2=dispbitcode[dispcount]; dispcount++;
if(dispcount==8)
{
dispcount=0;
}
ADC0809介绍 -常用 AD 转换器
ADC0809是美国国家半导体公司产品,它是逐次逼近型芯片,片内带有锁存功能的 8路模拟多路开关,可对 8路 0~~5V的输入模拟电压信号分时进行转换,片内具有多路开关 的地址译码和锁存电路、比较器、 256R 电阻 T 型网络、树状电子开关、逐次逼近寄存器 S AR ,控制与时序电路等。
输出具有 TTL 三态锁存缓冲器,可直接连到单片机数据总线。 ADC0809的分辨率为 8位, 单一 5V 供电,功耗为 15mW 。
ADC0809管脚图
AT89C51的硬件接口有三种方式:查询方式,中断方式,等待延时方式。本次设计主 要采用软件延时方式。本次设计的硬件连接也可采用查询方式。
A/D转换器 ADC0809与单片机的连接如图所示。 ADC0809的 IN0连接放大电路的输出。 ADC0809的时钟由 AT89C51的 ALE 提 供。
AD0809与主控制器的连接图
ADC0809引脚图与接口电路
发表日期:2008-5-8 14:43:08 有 1483位读者读过此文
A/D转换器芯片 ADC0809简介 8路模拟信号的分时采集,片内有 8路模拟选通开关,以及相应的通道抵制 锁存用译码电路,其转换时间为 100μs
左右。
图 9.8 《ADC0809引脚图》
1. ADC0809的内部结构
ADC0809的内部逻辑结构图如图 9-7所示。
图 9.7 《ADC0809内部逻辑结构》
图中多路开关可选通 8个模拟通道,允许 8路模拟量分时输入, 共用一个 A/D转换器进行转换,这 是一种经济的多路数据采集方法。地址锁存与译码电路完成对 A、B、C 3个地址位进行锁存和译码,其译 码输出用于通道选择,其转换结果通过三态输出锁存器存放、输出,因此可以直接与系统数据总线相连, 表 9-1为通道选择表。
表 9-1 通道选择表
2.信号引脚
ADC0809芯片为 28引脚为双列直插式封装,其引脚排列见图 9.8。
对 ADC0809主要信号引脚的功能说明如下:
IN7~IN0——模拟量输入通道
ALE——地址锁存允许信号。对应 ALE 上跳沿,A、B、C 地址状态送入地址锁存器中。
START——转换启动信号。START 上升沿时,复位 ADC0809;START 下降沿时启动芯片,开始进行 A/D转换;在 A/D转换期间,START 应保持 低电平。本信号有时简写为 ST.
A、B、C——地址线。 通道端口选择线,A 为低地址,C 为高地址,引脚图中为 ADDA,ADDB 和 ADDC。其地
址状态与通道对应关系见表 9-1。
CLK——时钟信号。ADC0809的内部没有时钟电路,所需时钟信号由外界提供,因此有时钟信号引脚。通常 使用频率为 500KHz 的时钟信号
EOC——转换结束信号。 EOC=0,正在进行转换;EOC=1,转换结束。 使用中该状态信号即可作为查询的状态标 志,又可作为中断请求信号使用。
D7~D0——数据输出线。为三态缓冲输出形式,可以和单片机的数据线直接相连。D0为最低位,D7为最高 OE——输出允许信号。 用于控制三态输出锁存器向单片机输出转换得到的数据。OE=0, 输出数据线呈高阻; OE=1,输出转换得到的数据。
Vcc—— +5V电源。
Vref——参考电源参考电压用来与输入的模拟信号进行比较,作为逐次逼近的基准。其典型值为
+5V(Vref(+)=+5V, Vref(-)=-5V).
9.2.2 MCS-51单片机与 ADC0809的接口
ADC0809与 MCS-51单片机的连接如图 9.10所示。
电路连接主要涉及两个问题。 一是 8路模拟信号通道的选择, 二是 A/D转换完成后转换数据的传送。 1. 8路模拟通道选择
图 9.10 ADC0809与 MCS-51的连接
如图 9.11所示模拟通道选择信号 A、B、C 分别接最低三位地址 A0、A1、A2即(P0.0、P0.1、P0.2), 而地址锁存允许信号 ALE 由 P2.0控制,则 8路模拟通道的地址为 0FEF8H~0FEFFH.此外,通道地址选择以 WR 作写选通信号,这一部分电路连接如图 9.12所示。
图 9.11 ADC0809
的部分信号连接
图 9.12 信号的时间配合
图 9.12是有关信号的时间配合示意图。 从图中可以看到, 把 ALE 信号与 START 信号接在一起了,这 样连接使得在信号的前沿写入(锁存)通道地址,紧接着在其后沿就启动转换。
启动 A/D转换只需要一条 MOVX 指令。 在此之前, 要将 P2.0清零并将最低三位与所选择的通道好像对 应的口地址送入数据指针 DPTR 中。例如要选择 IN0通道时,可采用如下两条指令,即可启动 A/D转换: MOV DPTR , #FE00H ;送入 0809的口地址
MOVX @DPTR , A ;启动 A/D转换(IN0)
注意:此处的 A 与 A/D转换无关,可为任意值。
2. 转换数据的传送
A/D转换后得到的数据应及时传送给单片机进行处理。数据传送的关键问题是如何确认 A/D转换的完 成,因为只有确认完成后,才能进行传送。为此可采用下述三种方式。
(1)定时传送方式
对于一种 A/D转换其来说, 转换时间作为一项技术指标是已知的和固定的。 例如 ADC0809转换时间为 128μs,相当于 6MHz 的 MCS-51单片机共 64个机器周期。可据此设计一个延时子程序,A/D转换启动后即 调用此子程序,延迟时间一到,转换肯定已经完成了,接着就可进行数据传送。
(2)查询方式
A/D转换芯片由表明转换完成的状态信号,例如 ADC0809的 EOC 端。因此可以用查询方式,测试 EOC 的状态,即可却只转换是否完成,并接着进行数据传送。
(3)中断方式
把表明转换完成的状态信号(EOC)作为中断请求信号,以中断方式进行数据传送。
不管使用上述那种方式, 只要一旦确定转换完成,即可通过指令进行数据传送。 首先送出口地址并以 RD 信
号有效时,OE 信号即有效,把转换数据送上数据总线,供单片机接受。
不管使用上述那种方式,只要一旦确认转换结束,便可通过指令进行数据传送。所用的指令为 MOVX 读指 令,仍以图 9-17所示为例,则有
MOV DPTR , #FE00H
MOVX A , @DPTR
该指令在送出有效口地址的同时,发出 RD 有效信号,使 0809的输出允许信号 OE 有
效,从而打开三态门输出,是转换后的数据通过数据总线送入 A 累加器中。
这里需要说明的示, ADC0809的三个地址端 A、 B、 C 即可如前所述与地址线相连, 也可与数据线相连, 例如与 D0~D2相连。 这是启动 A/D转换的指令与上述类似,只不过 A 的内容不能为任意数, 而必须和所选 输入通道号 IN0~IN7相一致。例如当 A、B、C 分别与 D0、D1、D2相连时,启动 IN7的 A/D转换指令如下: MOV DPTR, #FE00H ;送入 0809的口地址
MOV A ,#07H ;D2D1D0=111选择 IN7通道
MOVX @DPTR, A ;启动 A/D转换
9.2.3 A/D转换应用举例
设有一个 8路模拟量输入的巡回监测系统,采样数据依次存放在外部 RAM 0A0H~0A7H单元中,按图 9.10所示的接口电路,ADC0809的 8个通道地址为 0FEF8H~0FEFFH.其数据采样的初始化程序和中断服务 程序(假定只采样一次)如下:
初始化程序:
MOV R0, #0A0H;数据存储区首地址
MOV R2, #08H;8路计数器
SETB IT1;边沿触发方式
SETB EA ;中断允许
SETB EX1;允许外部中断 1中断
MOV DPTR, #0FEF8H;D/A转换器地址
LOOP: MOVX @DPTR, A ;启动 A/D转换
HERE: SJMP HERE;等待中断 中断服务程序: DJNZ R2, ADEND
MOVX A, @DPTR;数据采样
MOVX @R0, A;存数
INC DPTR;指向下一模拟通道
INC R0;指向数据存储器下一单元
MOVX @DPTR, A
AD END: RETI
模/数转换器芯片 ADC 0809
1. ADC 0809芯片的简介
图 8-3 ADC 0809内部逻辑框图
如 图 8-3,ADC0809具有 8个通道的模拟输入线(IN0~IN7),可在程序控制下对任意通道进 行 A/D转换,获得 8位二进制数字量(D7~D0)。
模拟输入部分有 8路多路开关,可由 3位地址输入 ADDA、ADDB、ADDC 的不同组合来选择,
ALE 为地址锁存信号, 高电平有效, 锁存这三条地址输入信号。 主体部分是采用逐次逼近式的 A/D转换电路,由 CLK 控制的内部电路的工作,START 为启动命令,高电平有效,启动 ADC0809内部 的 A/D转换,当转换完成,输出信号 EOC 有效,OE 为输出允许信号,高电平有效,打开输出三 态缓冲器,把转换后的结果送 DB。
工作过程:
1. 当模拟量送至某一输入通道 IN i 后,CPU 将标识该通道编码的三位地址信号经数据线或 地址线输入到 ADDC、ADDB、ADDA 引脚上。
2. 地址锁存允许 ALE 锁存这三位地址信号,启动命令 START 启动 A/D转换。
3. 转换开始,EOC 变低电平,转换结束,EOC 变为高电平。EOC 可作为中断请求信号。
4. 转换结束后,可通过执行 IN 指令,设法在输出允许 OE 脚上形成一个正脉冲,打开三态 缓冲器把转换的结果输入到 DB,一次 A/D转换便完成了。
2. ADC 0809同 CPU 的接口技术
由于 ADC0809输入端具有可控的三态输出门, 所以它既能同微处理器直接相连, 也能通过并 行接口芯片同微处理器连接。
(1)直接连接
图 8-4 ADC 0809直接与 CPU 相连
例:如图 8-4所示,假设输入通道 IN 7读入一个模拟量,那么经 ADC0809转换后进入微处理器的 程序:
MOV OUT AL,07H
84H,AL
;送输入通道号 7 ;并发出启动信号
CALL IN HLT DELAY
AL,84H
;延时等待转换结束,延时等于转换时间 ;转换结束,读入数据
(2)通过并行接口芯片同微处理器的连接
ADC0809通过并行接口芯片 8255A 与 CPU(或系统总线)相连的例子见典型例题。
范文三：QCN-SERIES中文资料
2 Way-90° 50? 330 to 3400 MHz
Power Splitters/Combiners
Ultra-Small Ceramic
QCN-SERIES
patent pending
元器件交易网www.cecb2b.com
QCN-12A
INSERTION LOSS
1.01.52.02.53.03.54.04.55.0800
850
900
950100010501100115012001250FREQUENCY (MHz)
I N S E R T I O N L O S S (d B )
QCN-12A ISOLATION 14.5
15.015.516.016.517.017.5800
850900950100010501100115012001250FREQUENCY (MHz)
I S O L A T I O N (d B
) QCN-12A
PHASE UNBALANCE
858789919395800
850900950100010501100115012001250FREQUENCY (MHz)
P H A S E U N B A L A N C E (d e g . )
QCN-5
INSERTION LOSS
1.01.52.02.53.03.54.04.55.0330
380
430480530
580
FREQUENCY (MHz)
I N S E R T I O N L O S S (d B )
QCN-5ISOLATION
051015202530330
380430480530580FREQUENCY (MHz)I S O L A T I O N (d B
) QCN-5
PHASE UNBALANCE
858789919395330
380430480530580
FREQUENCY (MHz)
P H A S E U N B A L A N C E (d e g . )
QCN-7
INSERTION LOSS1.0
1.5
2.02.53.03.54.04.55.0425450475500525550575600625650675
FREQUENCY (MHz)
I N S E R T I O N L O S S (d B )
QCN-7ISOLATION
13.5
14.0
14.515.015.516.016.5425450475500525550575600625650675
FREQUENCY (MHz)
I S O L A T I O N (d B
)
QCN-7
PHASE UNBALANCE
85
86
87888990425450475500525550575600625650675
FREQUENCY (MHz)
P H A S E U N B A L A N C E (d e g . )
QCN-12
INSERTION LOSS1.01.52.02.53.03.54.04.55.0800
900
1000110012001300
1400
FREQUENCY (MHz)
I N S E R T I O N L O S S (d B )
QCN-12ISOLATION
0510152025800
90010001100120013001400FREQUENCY (MHz)
I S O L A T I O N (d B
)
QCN-12
PHASE UNBALANCE
808182838485800
90010001100120013001400
FREQUENCY (MHz)
P H A S E U N B A L A N C E (d e g . )
QCN-19
1.0
1.5
2.02.53.03.54.04.55.0I N S E R T I O N L O S S (d B )
QCN-19QCN-19
QCN-25
INSERTION LOSS
1300
1500
1700190021002300
2500
FREQUENCY (MHz)
I N S E R
T I O N L O S S (d B )
QCN-25ISOLATION
1300
1500
1700
1900
2100
2300
2500
FREQUENCY (MHz)I S O L A T I O N (d B )
QCN-25
PHASE UNBALANCE
1300
150017001900210023002500
FREQUENCY (MHz)
P H A S E U N B A L A N C E (d e g . )
QCN-27
INSERTION LOSS
170018251950207522002325245025752700
FREQUENCY (MHz)
I N S E R T I O N L O S S (d B )
QCN-27ISOLATION
170018251950207522002325245025752700
FREQUENCY (MHz)
I S O L A T I O N (d B )
QCN-27
PHASE UNBALANCE
85
87
89919395170018251950207522002325245025752700
FREQUENCY (MHz)
P H A S E U N B A L A N C E (d e g . )
QCN-34
INSERTION LOSS
1.0
1.5
2.02.53.03.54.04.5
5.02500260027002800290030003100320033003400
FREQUENCY (MHz)
I N
S E R T I O N L O S S (d B )
QCN-34ISOLATION
2500260027002800290030003100320033003400
FREQUENCY (MHz)
I S O L A T I O N (d B )
QCN-34
PHASE UNBALANCE
85
87
899193952500260027002800290030003100320033003400
FREQUENCY (MHz)
P H A S E U N B A L A N C E (d e g . )
INTERNET http://www.minicircuits.com
P.O. Box 350166, Brooklyn, New York 11235-0003 (718) 934-4500 Fax (718) 332-4661
Distribution Centers NORTH AMERICA 800-654-7949 ? 417-335-5935 ? Fax 417-335-5945 ? EUROPE 44-1252-832600 ? Fax 44-1252-837010
Mini-Circuits
?Mini-Circuits ISO 9001 & ISO 14001 Certified
Page 3 of 3
范文四：LIPO中文资料
Lipofectamine ? 2000
Cat. No. 11668-027 Size: 0.75 ml Cat. No. 11668-019
Size: 1.5 ml
Contents and Storage
Lipofectamine ? 2000 is supplied in liquid form at a concentration of 1 mg/ml. Store at +4°C. DO NOT FREEZE. Product is guaranteed for 6 months from the date of shipment if stored properly.
Description
Lipofectamine ? 2000 is a proprietary formulation suitable for the transfection of nucleic acids into eukaryotic cells. Using Lipofectamine ? 2000 for transfection provides the following advantages: ?
The highest transfection efficiency in many cell types and formats (e.g. 96-well). Refer to the Transfection Collection and the Invitrogen Transfection Guide available at www.invitrogen.com for a list of cell lines and cell types that have been
successfully transfected. Detailed transfection procedures are also available. For a procedure to transfect mammalian cells with short interfering RNAs (siRNA) for use in RNA interference (RNAi) studies, see www.invitrogen.com\rnai. ? DNA-Lipofectamine ? 2000 complexes can be added directly to cells in culture medium (in the presence or absence of serum).
?
It is not necessary to remove complexes or change or add medium following transfection, although complexes can be removed after 4-6 hours without loss of activity.
Product Qualification
Lipofectamine ? 2000 is tested for the absence of microbial contamination using blood agar plates, Sabaraud dextrose agar plates, and fluid thioglycolate medium, and functionally by transfection of CHO-K1 cells with a luciferase reporter-containing plasmid.
Important Guidelines
Follow these guidelines when performing transfections:
1. The ratio of DNA (in μg):Lipofectamine? 2000 (in μl) to use when preparing complexes should be 1:2 to 1:3 for most cell
lines. Some optimization may be necessary. Example: To transfect 0.5-2 x 105 cells in a 24-well format, use 0.8-1 μg DNA and 2-3 μl of Lipofectamine? 2000. 2. Transfect cells at high cell density. 90-95% confluence at the time of transfection is recommended to obtain high efficiency
and expression levels, and to minimize decreased cell growth associated with high transfection activity. Lower cell densities are suitable with optimization of conditions. Take care to maintain a standard seeding protocol between experi-ments because transfection efficiency is sensitive to culture confluence. 3. Do not add antibiotics to media during transfection as this will cause cell death. For optimal results, we also recommend the following:
1. Use Opti-MEM ? I Reduced Serum Medium (Catalog no. 31985-062) to dilute Lipofectamine? 2000 prior to complexing with
DNA. Other media without serum (e.g. D-MEM) may be used to dilute Lipofectamine? 2000, but transfection efficiency may be compromised. 2. Test serum-free media formulations for compatibility with Lipofectamine? 2000 as some serum-free formulations can
inhibit cationic lipid-mediated transfection. CD 293, 293 SFM II, and VP-SFM are media formulations known to inhibit transfection.
Limited Use Label License No. 27
The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or
materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) to not transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Use of this product in conjunction with methods for the introduction of RNA molecules into cells may require licenses to one or more patents or patent applications. Users of these products should determine if any licenses are required. Invitrogen Corporation will not assert a claim against the buyer of infringement of patents owned by Invitrogen and claiming this product based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not
willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.
25-0489B
Doc. Rev. 102202
Page 2 Transfection Procedure
Use the following procedure to transfect mammalian cells in a 24-well format. To transfect cells in other formats, see Scaling Up or Down Transfections.
1. Adherent cells: One day before transfection, plate 0.5-2 x 105 cells in 500 μl of growth medium without antibiotics per well so that they will be 90-95% confluent at the time of transfection.
Suspension cells: On the day of transfection just prior to preparing complexes, plate 4-8 x 105 cells in 500 μl of growth medium without antibiotics per well.
2. For each transfection sample, prepare DNA-Lipofectamine? 2000 complexes as follows:
a. Dilute DNA in 50 μl of Opti-MEM? I Reduced Serum Medium without serum (or other medium without serum). Mix gently.
b. Mix Lipofectamine ? 2000 gently before use, then dilute the appropriate amount in 50 μl of Opti-MEM? I Medium (or other medium without serum). Mix gently and incubate for 5 minutes at room temperature. Note: Combine the
diluted Lipofectamine? 2000 with the diluted DNA within 30 minutes. Longer incubation times may decrease
activity. If D-MEM is used as a diluent for the Lipofectamine? 2000, mix with the diluted DNA within 5 minutes. c. After the 5 minute incubation, combine the diluted DNA with the diluted Lipofectamine? 2000 (total volume is
100 μl). Mix gently and incubate for 20 minutes at room temperature to allow the DNA-Lipofectamine? 2000
complexes to form. The solution may appear cloudy, but this will not inhibit the transfection. Note: DNA-
Lipofectamine ? 2000 complexes are stable for 6 hours at room temperature.
3. Add the 100 μl of DNA-Lipofectamine? 2000 complexes to each well containing cells and medium. Mix gently by rocking the plate back and forth.
4. Incubate the cells at 37°C in a CO2 incubator for 24-48 hours until they are ready to assay for transgene expression. It is not necessary to remove the complexes or change the medium; however, growth medium may be replaced after 4-6 hours without loss of transfection activity.
5. For stable cell lines: Passage the cells at a 1:10 or higher dilution into fresh growth medium 24 hours after transfection. Add selective medium the following day.
For suspension cells: Add PMA and/or PHA (if desired) 4 hours after adding the DNA-Lipofectamine? 2000 complexes to the cells. Tip: For Jurkat cells, adding PHA-L and PMA at final concentrations of 1 μg/ml and 50 ng/ml, respectively, enhances CMV promoter activity and gene expression. For K562 cells, adding PMA alone is sufficient to enhance
promoter activity.
Scaling Up or Down Transfections
To transfect cells in different tissue culture formats, vary the amounts of Lipofectamine? 2000, DNA, cells, and medium used in proportion to the difference in surface area (see table). With automated, high-throughput systems, larger complexing
volumes are recommended for transfections in 96-well plates. Note: You may perform rapid 96-well plate transfections (plate cells and transfect simultaneously) by adding a suspension of cells directly to complexes prepared in the plate. Prepare complexes and add cells at twice the cell density as in the basic protocol in a 100 μl volume. Cells will adhere as usual in the presence of DNA-Lipofectamine? 2000 complexes.
Culture Vessel
Surface Area
per Well (cm2)
Relative Surface
Area (vs. 24-well)
Volume of Plating
Medium
DNA (μg) and
Dilution Volume (μl)
Lipofectamine ? 2000 (μl) and Dilution Volume (μl) 0.2 100 μμg in 25 μμl in 25 μl
1 500 μμg in 50 μμl in 50 μl
2 1
ml 1.6 μg in 100 μμl in 100 μl
5 2
ml 4.0 μg in 250 μμl in 250 μl
5 2
ml 4.0 μg in 250 μμl in 250 μl
10 5
ml 8.0 μg in 0.5 ml 20 μl in 0.5 ml
30 15
ml 24 μg in 1.5 ml 60 μl in 1.5 ml
Note: Surface areas are determined from actual measurements of tissue culture vessels.
Optimizing Transfection
To obtain the highest transfection efficiency and low non-specific effects, optimize transfection conditions by varying DNA and Lipofectamine? 2000 concentrations, and cell density. Make sure that cells are greater than 90% confluent and vary DNA (μg):Lipofectamine? 2000 (μl) ratios from 1:0.5 to 1:5.
?2000-2002 Invitrogen Corporation. All rights reserved.
范文五：PDZ-B中文资料
Product speci?cation Supersedes data of 1998Jan 09 1998Apr 23
DISCRETE SEMICONDUCTORS元器件交易网www.cecb2b.com
Voltage regulator diodes
PDZ-B series
FEATURES
?Total power dissipation:max. 400mW
?Small plastic package suitable forsurface mounted design?Wide variety of voltage ranges:nom. 2.4to 36V (E24range). APPLICATIONS
?General voltage regulation.
DESCRIPTION
Low-power general purpose voltageregulator diodes in a small plasticSMD SOD323 package.
PINNING
MARKING
LIMITING VALUES
In accordance with the Absolute Maximum Rating System (IEC 134).Note
1. Device mounted on a printed-circuit board measuring 11×25×1.6mm.
Voltage regulator diodesPDZ-B series THERMAL CHARACTERISTICS
Note
1. Device mounted on a printed-circuit board measuring 11×25×1.6mm.
ELECTRICAL CHARACTERISTICS
Table 1Total series
T j =25°C unless otherwise specified.
Philips Semiconductors
Product speci?cation
Voltage regulator diodes
PDZ-B series
Voltage regulator diodesPDZ-B series GRAPHICAL DATA
Voltage regulator diodes
PDZ-B series
PACKAGE OUTLINE
SOD323
Plastic surface mounted package; 2 leads
元器件交易网www.cecb2b.com
Philips SemiconductorsProduct speci?cation Voltage regulator diodesPDZ-B series DEFINITIONS
LIFE SUPPORT APPLICATIONS
These products are not designed for use in life support appliances, devices, or systems where malfunction of these products can reasonably be expected to result in personal injury. Philips customers using or selling these products for use in such applications do so at their own risk and agree to fully indemnify Philips for any damages resulting from such improper use or sale.
Internet: http://www.semiconductors.philips.com
Philips Semiconductors – a worldwide company
? Philips Electronics N.V. 1998
SCA57
All rights are reserved. Reproduction in whole or in part is prohibited without the prior written consent of the copyright owner.
The information presented in this document does not form part of any quotation or contract, is believed to be accurate and reliable and may be changedwithout notice. No liability will be accepted by the publisher for any consequence of its use. Publication thereof does not convey nor imply any licenseunder patent- or other industrial or intellectual property rights.
Netherlands: Postbus90050, 5600PB EINDHOVEN, Bldg.VB, Tel. +31402782785, Fax. +31402788399
New Zealand: 2Wagener Place, C.P.O.Box 1041, AUCKLAND,Tel. +6498494160, Fax. +6498497811Norway: Box1, Manglerud0612, OSLO,Tel. +4722748000, Fax. +4722748341
Philippines: Philips Semiconductors Philippines Inc.,
106Valero St. Salcedo Village, P.O.Box 2108MCC, MAKATI, Metro MANILA, Tel.+6328166380, Fax. +6328173474Poland: Ul.Lukiska 10, PL04-123WARSZAWA, Tel. +48226122831, Fax. +48226122327Portugal: seeSpain Romania: seeItaly
Russia: Philips Russia, Ul.Usatcheva 35A, 119048MOSCOW, Tel. +70957556918, Fax. +70957556919
Singapore: Lorong1, ToaPayoh, SINGAPORE1231, Tel. +653502538, Fax. +652516500Slovakia: seeAustria Slovenia: seeItaly
South Africa: S.A. PHILIPS Pty Ltd., 195-215Main Road Martindale, 2092JOHANNESBURG, P.O.Box 7430 Johannesburg2000, Tel. +27114705911, Fax. +27114705494
South America: Al.Vicente Pinzon,173, 6thfloor, 04547-130S?OPAULO, SP, Brazil,
Tel. +55118212333, Fax. +55118212382Spain: Balmes22, 08007BARCELONA, Tel. +3433016312, Fax. +3433014107
Sweden: Kottbygatan7, Akalla, S-16485STOCKHOLM, Tel. +4686322000, Fax. +4686322745
Switzerland: Allmendstrasse140, CH-8027ZüRICH,Tel. +4114882686, Fax. +4114883263
Taiwan: Philips Semiconductors, 6F, No.96, ChienKuo N. Rd., Sec. 1, TAIPEI, Taiwan Tel.+886221342865, Fax. +886221342874Thailand: PHILIPS ELECTRONICS (THAILAND) Ltd.,
209/2Sanpavuth-Bangna Road Prakanong, BANGKOK10260, Tel. +6627454090, Fax. +6623980793
Turkey: Talatpasa Cad. No.5, 80640GüLTEPE/ISTANBUL,Tel. +902122792770, Fax. +902122826707
Ukraine : PHILIPS UKRAINE, 4Patrice Lumumba str., BuildingB, Floor7, 252042KIEV, Tel.+380442642776, Fax. +380442680461
United Kingdom: Philips Semiconductors Ltd., 276Bath Road, Hayes,MIDDLESEX UB35BX, Tel.+441817305000, Fax. +441817548421United States: 811East Arques Avenue, SUNNYVALE, CA94088-3409, Tel. +18002347381
Uruguay: seeSouth AmericaVietnam: seeSingapore
Yugoslavia: PHILIPS, TrgN. Pasica5/v, 11000BEOGRAD, Tel. +38111625344, Fax.+38111635777
For all other countries apply to: Philips Semiconductors,
International Marketing &Sales Communications,Building BE-p, P.O.Box 218, 5600MD EINDHOVEN, TheNetherlands, Fax. +31402724825Argentina: seeSouth America
Australia: 34 Waterloo Road, NORTH RYDE, NSW 2113,Tel. +61298054455, Fax. +61298054466
Austria:Computerstr. 6, A-1101 WIEN, P.O. Box213, Tel.+431601010, Fax. +431601011210
Belarus: Hotel Minsk Business Center, Bld.3, r.1211, VolodarskiStr. 6, 220050MINSK, Tel.+375172200733, Fax. +375172200773Belgium: seeThe NetherlandsBrazil:see South America
Bulgaria:Philips Bulgaria Ltd., Energoproject, 15thfloor, 51James Bourchier Blvd., 1407SOFIA, Tel. +3592689211, Fax. +3592689102
Canada: PHILIPS SEMICONDUCTORS/COMPONENTS,Tel. +18002347381
China/Hong Kong: 501Hong Kong Industrial Technology Centre,72Tat Chee Avenue, Kowloon Tong, HONG KONG,Tel. +85223197888, Fax. +85223197700Colombia: seeSouth AmericaCzech Republic: seeAustria
Denmark: PragsBoulevard 80, PB1919, DK-2300COPENHAGEN S, Tel. +4532882636, Fax. +4531570044Finland: Sinikalliontie3, FIN-02630ESPOO, Tel. +3589615800, Fax. +358961580920
France: 51Rue Carnot, BP317, 92156SURESNES Cedex,Tel. +33140996161, Fax. +33140996427
Germany: Hammerbrookstra?e69, D-20097HAMBURG, Tel. +4940235360, Fax. +494023536300
Greece: No.15, 25th March Street, GR17778TAVROS/ATHENS,Tel. +3014894339/239,Fax. +3014814240Hungary:see Austria
India: Philips INDIA Ltd, Band Box Building, 2nd floor,254-D, Dr. Annie Besant Road, Worli, MUMBAI400025, Tel. +91224938541, Fax. +91224930966Indonesia: seeSingapore
Ireland: Newstead, Clonskeagh, DUBLIN14, Tel. +35317640000, Fax. +35317640200
Israel: RAPACElectronics, 7Kehilat Saloniki St, PO Box 18053,TEL AVIV 61180, Tel.+97236450444, Fax. +97236491007Italy: PHILIPS SEMICONDUCTORS, PiazzaIV Novembre 3, 20124MILANO, Tel.+39267522531, Fax. +39267522557
Japan: PhilipsBldg 13-37, Kohnan2-chome, Minato-ku, TOKYO108, Tel. +81337405130, Fax. +81337405077
Korea: PhilipsHouse, 260-199Itaewon-dong, Yongsan-ku, SEOUL,Tel. +8227091412, Fax. +8227091415
Malaysia: No.76Jalan Universiti, 46200PETALING JAYA, SELANGOR,Tel. +60 37505214, Fax. +6037574880
Mexico: 5900Gateway East, Suite200, ELPASO, TEXAS79905, Tel. +9-58002347381Middle East: seeItaly
Printed in The Netherlands
115104/00/03/pp8 Date of release: 1998Apr 23Document order number: 939775003729
元器件交易网www.cecb2b.com
